Zepbound (tirzepatide), made by Eli Lilly & Co. Fortune 500, over competitor Wegovy (semaglutide), a Global 500 product of Novo Nordisk, in a randomized clinical trial conducted from 2023 to 2024 supported by Lilly.
Shelby Knowles – Bloomberg/Getty Images
